CollPlant Biotechnologies (NASDAQ:CLGN) reported Q2 earnings of $0.52 per share, beating the analyst consensus estimate of $0.01 by 5100 percent. This is a 244.44 percent increase over losses of $(0.36) per share from the same period last year. The company also reported quarterly sales of $10.18 million, beating the analyst consensus estimate of $5.15 million by 97.75 percent. This is a 15.33K percent increase over sales of $66.00 thousand the same period last year.